PIK3CA and endometrial cancer: In gynecologic oncology, Matulonis et al. (2015) highlighted the clinical significance of this approach by demonstrating a robust correlation between ctDNA-based MRD monitoring of PIK3CA mutations and treatment response in patients with advanced or recurrent endometrial cancer receiving pilaralisib therapy [110].